MDGL vs VKTX
MDGL: Madrigal is a commercial-stage biotech company exclusively focused on Rezdiffra, the first FDA-approved treatment for MASH with moderate-to-advanced fibrosis, now scaling US and EU commercialization. VKTX: Viking is developing VK2735, a novel dual GLP-1/GIP receptor agonist in Phase 3 trials for obesity and metabolic disorders, targeting a high-growth market currently dominated by single-agent GLP-1 therapies.
Side-by-side fundamentals
| Metric | MDGL | VKTX | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $537.65 | $37.31 | |
| Market cap as of 2026-07-23 | $12.4B | $4.3B | |
| PEG as of 2026-07-23 | n/a | -0.04 | |
| Net margin as of 2026-07-23 | -27.3% | n/a | |
| Gross margin as of 2026-07-23 | +93.1% | n/a | |
| Operating margin as of 2026-07-23 | -27.9% | n/a | |
| ROE as of 2026-07-23 | -50.1% | -71.3% | MDGL higher |
| ROA as of 2026-07-23 | -25.4% | -65.3% | MDGL higher |
| Debt / equity as of 2026-07-23 | 0.63 | 0.00 | VKTX lower |
| Revenue growth (YoY) as of 2026-07-23 | +256.8% | n/a | |
| Beta as of 2026-07-23 | -1.06 | 0.65 | |
| 1-year return as of 2026-07-22 close | +71.6% | +16.2% | MDGL higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.